• Milestone reached in Target Discovery Alliance
    Neil Torbett

News & Views

Milestone reached in Target Discovery Alliance

Since entering a multi-project target discovery collaboration in January 2020, when PhoreMost deployed its phenotypic screening platform, SITESEEKER®, towards disease-relevant pathways selected by Boehringer Ingelheim, PhoreMost has triggered a milestone payment, achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies to transform patients’ lives.

“The success of this project to date provides significant validation of our SITESEEKER platform and its capabilities in novel target discovery and is testament to the expertise and great collaborative efforts of the teams at both PhoreMost and Boehringer Ingelheim. We are proud to contribute to the development of much needed new therapies for patients by delivering on this first key milestone and look forward to continuing this very fruitful partnership” said Dr. Neil Torbett, Chief Executive Officer, PhoreMost.

The development of potential new therapies will now be continued at Boehringer Ingelheim leading to possible further success based pre-clinical, clinical and commercial milestone payments.

Further information online


Digital Edition

Lab Asia 31.6 Dec 2024

December 2024

Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...

View all digital editions

Events

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

SLAS 2025

Jan 25 2025 San Diego, CA, USA

Arab Health

Jan 27 2025 Dubai, UAE

Nano Tech 2025

Jan 29 2025 Tokyo, Japan

View all events